Theraclion appoints Yann Duchesne as Chairman of its Board of Directors

– FRANCE, Malakoff –  Theraclion (EPA: ALTHE), an innovative company developing a scalable robotic platform for noninvasive echotherapy, today announced the appointment of Yann Duchesne as Chairman of its Board of Directors, replacing Christopher Bödtker after his tragic death in mid-December.

About Yann Duchesne

Yann Duchesne is a seasoned French executive and CEO who served on numerous boards globally. He will lead Theraclion to the next level of development and value creation.

Ex-Mckinsey Managing Partner for France, Yann Duchesne was then a Senior Partner in a leading Private Equity in London, before becoming the CEO of a major industrial and commercial conglomerate. During the past 20 years, he has been on many Boards of listed or private equity-owned companies, frequently as Chairman. In the healthcare space, Yann served many significant pharma companies while at McKinsey and today is the chairman of a pharmaceutical group (Medis) and is a founding shareholder in a California-based biotech (Phylex).

About Theraclion

At Theraclion we believe that surgery, as we know it, is outdated. It converts optimistic patients into anxious individuals, brilliant doctors into exhausted system executors, and stretches healthcare systems to the limit. We have disrupted this convention by creating extracorporeal treatment platforms. We replace surgery with a robotic treatment from outside the body using High-Intensity Focussed Ultrasound (HIFU). Our leading-edge echotherapy platforms are currently CE marked in the non-invasive treatment of varicose veins with SONOVEIN® and of breast fibroadenomas and thyroid nodules with Echopulse®.

Located in Malakoff, near Paris, our employees live and breath innovation by extensive clinical research and harness artificial intelligence. The market of varicose veins treatment alone requires around 5 million procedures annually. It is a dynamic market in which we change paradigms by making non-invasive echotherapy the new standard.

For more information, please visit www.theraclion.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.